Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT06585033
Recruiting Not applicable

Placebo Effect In Spinal Cord Electrical Stimulation for Pain

NCT06585033 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2024-11-15
Last updated
2025-12-02

Condition(s) studied

Chronic Postoperative Pain

Investigational drug(s) / intervention(s)

Spinal cord stimulationSpinal cord stimulation

Spinal cord stimulation: Stimulation off

Spinal cord stimulation: Stimulation on

Study summary

Objective: To evaluate if spinal cord stimulation (SCS) performs better than placebo (no stimulation) in the long term to reduce persistent neuropathic leg pain refractory to medication and other conservative treatments in patients who have undergone lumbar spinal surgery.

Study design: Multicenter, double blind, randomized, sham-controlled trial.

After a positive SCS test trial, participants (18-70 years) will be implanted with a non-rechargeable SCS system providing active, subthreshold stimulation and followed for 12 months in a blinded cross-over design. The primary outcome measure is the difference in change in leg pain intensity scores using the Numeric Rating Scale (NRS) between a 3-month period with optimized subthreshold stimulation, and a 3-month period with no stimulation, as compared to baseline. Quality of life, physical functioning, sleep quality, return to work, and reduction in medication use will also be investigated.

Background: Up to 20% of patients who have undergone lumbar spinal surgery experience persistent back/leg pain leading to long-term reduction in functionality and quality of life. SCS is an established and safe, minimally invasive treatment for these patients when no further surgery is indicated and conservative therapies have been found to be ineffective. Placebo-controlled studies, comparing active and sham stimulation, were lacking until recently as traditional SCS relied on the patient feeling the stimulation (paresthesia). Technological progress with development of paresthesia-free stimulation forms now allows for the execution of placebo-controlled studies. A recent trial showing no significant difference in long-term effectiveness between active SCS and sham suffers from significant methodological shortcomings. This necessitates further sham-controlled studies to determine the effectiveness of SCS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * History consistent with PSPS2 of at least 6 months after the last spinal surgery. The patient experienced no effect of conservative treatments and has been assessed as not eligible for further spinal surgery. * Patients between 18-70 years of age. * Average perceived pain intensity in one or both legs of 5 or more and average perceived pain intensity in the back of less than 3 measured with the validated 11-box NRS (0 no pain, 10 worst imaginable pain) * The patient should have been informed verbally and in writing about the study and should have provided informed written consent to participate. * Adequate pain relief effect (50% or more) after a two week trial with active test stimulation. Exclusion Criteria: * Subject is unable to understand or operate the SCS device. * Subject currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system. * Ongoing coagulation disorder. * Ongoing abuse of alcohol, drugs, or prescription opioids. * Active debilitating psychiatric illness. * Active malignancy. * Condition with increased general infection sensitivity, such as known immunodeficiency. * Expected lifespan \<1 year. * Ongoing local infection or other skin disease where the IPG is planned to be placed. * Pregnancy.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Department of Anaesthesiology and Pain Management, Rijnstate Hospital Arnhem Netherlands Recruiting
Department of Neurosurgery, Stavanger University hospital Stavanger Norway Recruiting
Department of Neurosurgery, Sahlgrenska University Hospital Gothenburg Sweden Recruiting
Department of Anesthesiology and Intensive Care/Pain Center, Sahlgrenska University Hospital Östra Gothenburg Sweden Recruiting

More Sahlgrenska University Hospital trials in Sweden

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06585033 on ClinicalTrials.gov ↗ ← All trials in Sweden